X

Trial Profile

A Study of Bortezomib With Chemotherapy for Relapsed/Refractory Acute Lymphoblastic Leukemia.

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 21 Feb 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bortezomib (Primary) ; Cytarabine; Dexamethasone; Dexamethasone; Doxorubicin; Methotrexate; Pegaspargase; Vincristine
Indications Precursor cell lymphoblastic leukaemia-lymphoma
Focus Adverse reactions; Therapeutic Use

Most Recent Events

18 May 2012 Actual patient number 31 added as reported by ClinicalTrials.gov.
14 Dec 2011 Status changed from recruiting to completed.
13 Dec 2011 Results presented at the 53rd Annual Meeting and Exposition of the American Society of Hematology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com